Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis

Risk of Cardiovascular Events Associated With Current Exposure to HIV Antiretroviral Therapies in a US Veteran Population

(2015) Manisha Desai et al.   CLINICAL INFECTIOUS DISEASES

HIV infection and cardiovascular disease

(2014) L. G. Hemkens et al.   EUROPEAN HEART JOURNAL

Virological efficacy of abacavir: systematic review and meta-analysis

(2014) M. Cruciani et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Reducing waste from incomplete or unusable reports of biomedical research

(2014) Paul Glasziou et al.   LANCET

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

(2014) François Raffi et al.   LANCET

The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health

(2014) Roger J. Bedimo et al.   PLoS One

Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1

(2013) Eric S. Daar   ANNALS OF INTERNAL MEDICINE

A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients

(2013) CN Menezes et al.   HIV MEDICINE

Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naive Japanese Patients with HIV-1 Infection: A Randomized Multicenter Trial

(2013) Takeshi Nishijima et al.   INTERNAL MEDICINE

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents

(2012) Roger Bedimo et al.   AIDS

A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine

(2012) Nittaya Phanuphak et al.   ANTIVIRAL THERAPY

Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis

(2012) Fakhrul M Islam et al.   BMC PUBLIC HEALTH

The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial

(2012) CN Menezes et al.   HIV MEDICINE

Maraviroc Once-Daily Nucleoside Analog-Sparing Regimen in Treatment-Naive Patients

(2012) Anthony Mills et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

(2012) Thomas B. Campbell et al.   PLOS MEDICINE

Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons

(2011) Andy I Choi et al.   AIDS

Incidence of low and high-energy fractures in persons with and without HIV infection

(2011) Ann-Brit E. Hansen et al.   AIDS

Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: ACTG Study A5224s

(2011) G. A. McComsey et al.   CLINICAL INFECTIOUS DISEASES

Examination of Noninferiority, Safety, and Tolerability of Lopinavir/ritonavir and Raltegravir Compared with Lopinavir/ritonavir and Tenofovir/ Emtricitabine in Antiretroviral-Naïve Subjects: The PROGRESS Study, 48-Week Results

(2011) Jacques Reynes et al.   HIV CLINICAL TRIALS

Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results

(2011) Paul E. Sax et al.   JOURNAL OF INFECTIOUS DISEASES

Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

(2011) Grace A. McComsey et al.   JOURNAL OF INFECTIOUS DISEASES

Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study

(2010) Hans‐Jürgen Stellbrink et al.   CLINICAL INFECTIOUS DISEASES

Systematic Review and Meta‐analysis: Renal Safety of Tenofovir Disoproxil Fumarate in HIV‐Infected Patients

(2010) Ryan D. Cooper et al.   CLINICAL INFECTIOUS DISEASES

Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites

(2010) WH Belloso et al.   HIV MEDICINE

Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study

(2010) Frank A Post et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

(2009) Kimberly Y Smith et al.   AIDS

Simplification of Antiretroviral Therapy with Tenofovir‐Emtricitabine or Abacavir‐Lamivudine: A Randomized, 96‐Week Trial

(2009) Allison Martin et al.   CLINICAL INFECTIOUS DISEASES

Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients

(2009) Jose R Arribas et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy

(2009) Paul E. Sax et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand

(2008) Gail V. Matthews et al.   HEPATOLOGY

Reasons or excuses for avoiding meta-analysis in forest plots

(2008) John P A Ioannidis et al.   BMJ-British Medical Journal